4//SEC Filing
Vitae Pharmaceuticals, Inc 4
Accession 0001104659-16-151944
CIK 0001157602operating
Filed
Oct 24, 8:00 PM ET
Accepted
Oct 25, 4:33 PM ET
Size
13.4 KB
Accession
0001104659-16-151944
Insider Transaction Report
Form 4
HAYDEN DONALD J JR
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-10-25$8.57/sh−10,000$85,700→ 0 totalExercise: $12.43Exp: 2025-05-27→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-10-25$13.00/sh−17,000$221,000→ 0 totalExercise: $8.00Exp: 2024-09-23→ Common Stock (17,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-10-25$15.71/sh−18,182$285,639→ 0 totalExercise: $5.29Exp: 2024-06-24→ Common Stock (18,182 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-10-25$11.38/sh−10,000$113,800→ 0 totalExercise: $9.62Exp: 2026-05-25→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
- [F2]This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
- [F3]This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
- [F4]This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
- [F5]This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Documents
Issuer
Vitae Pharmaceuticals, Inc
CIK 0001157602
Entity typeoperating
Related Parties
1- filerCIK 0001157602
Filing Metadata
- Form type
- 4
- Filed
- Oct 24, 8:00 PM ET
- Accepted
- Oct 25, 4:33 PM ET
- Size
- 13.4 KB